Stockscreener 앱 받기
1.694
0.88%
-0.006
전일 마감가:
$1.70
열려 있는:
$1.69
하루 거래량:
545.45K
Relative Volume:
0.13
시가총액:
$143.94M
수익:
$1,000.00K
순이익/손실:
$-58.01M
주가수익비율:
-1.9613
EPS:
-0.8637
순현금흐름:
$-43.20M
1주 성능:
-3.71%
1개월 성능:
+0.30%
6개월 성능:
-12.24%
1년 성능:
-15.33%
1일 변동 폭
$1.64
$1.70
1주일 범위
$1.64
$1.79
52주 변동 폭
$0.6254
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
명칭
Milestone Pharmaceuticals Inc
전화
(514) 336-0444
주소
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.69 | 144.79M | 1,000.00K | -58.01M | -43.20M | -0.8637 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.54 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.00 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.44 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.02 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-09-11 | 개시 | Wells Fargo | Overweight |
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-06-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-22 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | 개시 | H.C. Wainwright | Buy |
| 2020-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-07-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-03-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | 개시 | Oppenheimer | Outperform |
| 2019-06-03 | 개시 | Cowen | Outperform |
| 2019-06-03 | 개시 | Jefferies | Buy |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
Investment Review: Should I invest in Milestone Pharmaceuticals Inc before earningsQuarterly Profit Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Milestone Pharmaceuticals (MIST) Highlights Etripamil's Safety a - GuruFocus
Milestone Pharmaceuticals to Present Data on CARDAMYST (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - Bitget
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session - The Manila Times
FDA-approved PSVT nasal spray shows minimal blood pressure change - Stock Titan
Boxer Capital Management LLC Invests $1.33 Million in Milestone Pharmaceuticals Inc. $MIST - MarketBeat
Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality - Seeking Alpha
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Milestone Pharmaceuticals Sets March 20 Call for 2025 Results and Business Update - TipRanks
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 - Bitget
Milestone Pharma sets Mar. 20 call to review 2025 results - Stock Titan
Swing Trade: What is the long term forecast for Milestone Pharmaceuticals Inc stockWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Wells Fargo Initiates Coverage of Milestone Pharmaceuticals (MIST) with Overweight Recommendation - MSN
Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Stock Report: Does Milestone Pharmaceuticals Inc have consistent dividend growthRecession Risk & Safe Entry Point Alerts - baoquankhu1.vn
Earnings Report: Should I invest in Milestone Pharmaceuticals Inc before earningsShare Buyback & Growth Oriented Trading Recommendations - baoquankhu1.vn
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - MSN
Milestone Pharmaceuticals Inc. $MIST Shares Purchased by Propel Bio Management LLC - MarketBeat
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Thursday - MarketBeat
MIST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Trend Review: Can Milestone Pharmaceuticals Inc beat the S P 500Earnings Growth Report & Expert Curated Trade Setups - baoquankhu1.vn
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update - MarketBeat
Aug Outlook: Can Milestone Pharmaceuticals Inc beat the S P 500Portfolio Gains Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Milestone Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Zacks Research Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Hold - MarketBeat
BlackRock HPS Credit Strategies Fund's Milestone Pharmaceuticals Inc(MIST) Holding History - GuruFocus
Risk Recap: What is the long term forecast for Milestone Pharmaceuticals Inc stockJuly 2025 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Does Milestone Pharmaceuticals Inc. have consistent dividend growthQuarterly Investment Review & AI Powered Buy and Sell Recommendations - mfd.ru
What is Milestone Pharmaceuticals Inc.’s book value per shareJuly 2025 Retail & Capital Efficient Trade Techniques - mfd.ru
Is Milestone Pharmaceuticals Inc.’s ROIC above industry average2025 Top Gainers & Safe Entry Trade Signal Reports - mfd.ru
Milestone Pharmaceuticals - WCIV
Why Milestone Pharmaceuticals Inc. stock is a value investor pick2025 Bull vs Bear & Community Consensus Trade Signals - mfd.ru
Why analysts upgrade Milestone Pharmaceuticals Inc. stock2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
MIST Should I Buy - Intellectia AI
Milestone Appoints David Sandoval as General Counsel - Intellectia AI
MIST SEC FilingsMilestone Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Will Milestone Pharmaceuticals Inc. stock split attract more investorsMarket Growth Report & Real-Time Buy Signal Notifications - mfd.ru
What is the long term forecast for Milestone Pharmaceuticals Inc. stock2025 Biggest Moves & Daily Profit Maximizing Tips - mfd.ru
What are the risks of holding Milestone Pharmaceuticals Inc.July 2025 Summary & Risk Adjusted Buy and Sell Alerts - mfd.ru
Milestone Pharmaceuticals appoints David Sandoval as general counsel By Investing.com - Investing.com Australia
Milestone Pharmaceuticals appoints David Sandoval as general counsel - Investing.com Nigeria
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer - The Manila Times
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Milestone Pharmaceuticals (MIST) CFO updates 204,000-share option to $1.96 - Stock Titan
Milestone Pharmaceuticals (MIST) Awards New Equity Options - GuruFocus
Milestone Pharmaceuticals reports inducement grants under Nasdaq listing rule - TipRanks
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-02-03 14:31:32 - baoquankhu1.vn
Market Review: Is Milestone Pharmaceuticals Inc a momentum stockJuly 2025 Recap & Daily Oversold Bounce Ideas - baoquankhu1.vn
Milestone Pharmaceuticals Inc (MIST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Milestone Pharmaceuticals Inc 주식 (MIST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bharucha David | Chief Medical Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
113,181 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
41,993 |
| Nelson Jeffrey Edward | Chief Operating Officer |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
49,848 |
| Muller Lorenz | Chief Commercial Officer |
Dec 15 '25 |
Sale |
2.32 |
53,566 |
124,273 |
196,486 |
| Muller Lorenz | Chief Commercial Officer |
Jan 26 '26 |
Sale |
1.93 |
11,180 |
21,577 |
205,406 |
| Hasija Amit | CFO & EVP of Corp. Development |
Dec 15 '25 |
Sale |
2.32 |
58,007 |
134,576 |
91,993 |
| Hasija Amit | CFO & EVP of Corp. Development |
Jan 26 '26 |
Sale |
1.93 |
12,245 |
23,633 |
99,848 |
| Oliveto Joseph | President and CEO |
Dec 15 '25 |
Sale |
2.32 |
133,054 |
308,685 |
450,667 |
| Oliveto Joseph | President and CEO |
Jan 26 '26 |
Sale |
1.93 |
34,523 |
66,629 |
482,744 |
| Oliveto Joseph | President and CEO |
Jan 08 '26 |
Sale |
2.25 |
43,000 |
96,750 |
303,721 |
1.42%
1.08%
자본화:
|
볼륨(24시간):